Literature DB >> 23584048

Analytical power of LLE-HPLC-PDA-MS/MS in drug metabolism studies: identification of new nabumetone metabolites.

Milan Nobilis1, Jiří Mikušek, Barbora Szotáková, Robert Jirásko, Michal Holčapek, Chamseddin Chamseddin, Thomas Jira, Radim Kučera, Jiří Kuneš, Milan Pour.   

Abstract

Nabumetone is a non-acidic, nonsteroidal anti-inflammatory prodrug. Following oral administration, the prodrug is converted in the liver to 6-methoxy-2-naphthylacetic acid (6-MNA), which was found to be the principal metabolite responsible for the NSAID effect. The pathway of nabumetone transformation to 6-MNA has not been clarified, with no intermediates between nabumetone and 6-MNA having been identified to date. In this study, a new, as yet unreported phase I metabolite was discovered within the evaluation of nabumetone metabolism by human and rat liver microsomal fractions. Extracts from the biomatrices were subjected to chiral LLE-HPLC-PDA and achiral LLE-UHPLC-MS/MS analyses to elucidate the chemical structure of this metabolite. UHPLC-MS/MS experiments detected the presence of a structure corresponding to elemental composition C15H16O3, which was tentatively assigned as a hydroxylated nabumetone. Identical nabumetone and HO-nabumetone UV spectra obtained from the PDA detector ruled out the presence of the hydroxy group in the aromatic moiety of nabumetone. Hence, the most likely structure of the new metabolite was 4-(6-methoxy-2-naphthyl)-3-hydroxybutan-2-one (3-hydroxy nabumetone). To confirm this structure, the standard of this nabumetone metabolite was synthesized, its spectral (UV, CD, NMR, MS/MS) and retention properties on chiral and achiral chromatographic columns were evaluated and compared with those of the authentic nabumetone metabolite. To elucidate the subsequent biotransformation of 3-hydroxy nabumetone, the compound was used as a substrate in incubation with human and rat liver microsomal fraction. A number of 3-hydroxy nabumetone metabolites (products of conjugation with glucuronic acid, O-desmethylation, carbonyl reduction and their combination) were discovered in the extracts from the incubated microsomes using LLE-HPLC-PDA-MS/MS experiments. On the other hand, when 3-hydroxy nabumetone was incubated with isolated rat hepatocytes, 6-MNA was detected as the principal metabolite of 3-hydroxy nabumetone. Hence, 3-hydroxy nabumetone could be the missing link in nabumetone biotransformation to 6-MNA (i.e. nabumetone3-hydroxy nabumetone6-MNA).
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23584048     DOI: 10.1016/j.jpba.2013.03.006

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  3 in total

1.  Carbon-carbon bond cleavage in activation of the prodrug nabumetone.

Authors:  Fatbardha Varfaj; Siti N A Zulkifli; Hyoung-Goo Park; Victoria L Challinor; James J De Voss; Paul R Ortiz de Montellano
Journal:  Drug Metab Dispos       Date:  2014-02-28       Impact factor: 3.922

2.  Presence or absence of microbiome modulates the response of mice organism to administered drug nabumetone.

Authors:  L Jourová; B Lišková; K Lněničková; N Zemanová; P Anzenbacher; P Hermanová; T Hudcovic; H Kozáková; E Anzenbacherová
Journal:  Physiol Res       Date:  2020-12-31       Impact factor: 1.881

3.  Gel Formulation of Nabumetone and a Newly Synthesized Analog: Microemulsion as a Photoprotective Topical Delivery System.

Authors:  Fedora Grande; Gaetano Ragno; Rita Muzzalupo; Maria Antonietta Occhiuzzi; Elisabetta Mazzotta; Michele De Luca; Antonio Garofalo; Giuseppina Ioele
Journal:  Pharmaceutics       Date:  2020-05-05       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.